Observational studyCancer reports (Hoboken, N.J.)2025

Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.

Oscar C Y Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.